Medicine in China

Q&A: Transcenta sees promising future in biologics

The biopharmaceutical startup backed by Lilly Asia Ventures, Temasek and Sequoia China is looking both at its next round of funding and at an IPO next year.

Over the past five years, biotech investment has experienced the fastest development in China. Pharmaceutical companies have become a rising force that has attracted increasing amount of capital.  

Transcenta is a biotech company that is riding this momentum.  

In an interview with Transcenta’s chief executive Xueming Qian and chairman Jonathan Zhao, the two founders share their vision and future plans for the young company. Transcenta was founded in January this year when HJB and MabSpace came together. HJB was focused on bioprocessing technology that accelerates manufacturing, while MabSpace provides discovery, clinical stage research for biologic medicines. 

 

...
¬ Haymarket Media Limited. All rights reserved.

FinanceAsia has updated its subscription model.

Registered readers now have the opportunity to read 5 articles from our award-winning website for free.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences.

To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222

Article limit is reached.

Hello! You have used up all of your free articles on FinanceAsia.

To obtain unlimited access to our award-winning exclusive news and analysis, we offer subscription packages, including single user, team (2-10 users), or office-wide licences. To help you and your colleagues access our proprietary content, please contact us at subscriptions@financeasia.com, or +(852) 2122 5222